Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov124310.25208/vdv1243GUIDELINES FOR PRACTITIONERSВ ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУResearch ArticleRhinophyma: patient managementРинофима: тактика ведения пациентаhttps://orcid.org/0000-0002-7689-83506938-4768DrozhdinaMarianna B.ДрождинаМарианна Борисовна
Russian Federation

MD, Cand Sci. (Med.), assistant professor

к.м.н., доцент

drozhdina@yandex.ruhttps://orcid.org/0000-0003-2306-14232534-4480BobroVarvara A.БоброВарвара Андреевна
Russian Federation

postgraduate student

аспирант

bobro.va@inbox.ruKirov State Medical AcademyКировский государственный медицинский университет1501202298164710205202131012022Copyright ©; 2022, Drozhdina M.B., Bobro V.A.Copyright ©; 2022, Дрождина М.Б., Бобро В.А.2022Drozhdina M.B., Bobro V.A.Дрождина М.Б., Бобро В.А.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/1243

Rhinophyma is a rare subtype of rosacea, which is a thickening of the skin in the nasal area due to an overgrowth of the sebaceous glands and the underlying connective tissue. The exact pathogenesis of rhinophyma is unknown, but potential factors include a combination of neurovascular disorders, innate immune responses, and the presence of microorganisms. The article presents current data on the treatment of rosacea, in particular, rhinophyma. A clinical case of a 67-year-old patient with a combination of papulo-pustular subtype of rosacea and rhinophyma is presented. The high effectiveness of the therapy with systemic isotretinoin was demonstrated.

Ринофима — редкий подтип розацеа, который представляет собой утолщение кожи в области носа вследствие разрастания сальных желез и подлежащей соединительной ткани. Точный патогенез ринофимы неизвестен, но потенциальные факторы включают сочетание нервно-сосудистых нарушений, врожденных иммунных ответов, присутствие микроорганизмов. В статье приводятся современные данные о лечении розацеа, в частности, ринофимы. Представлен клинический случай пациента 67 лет с сочетанием папуло-пустулезного подтипа розацеа и ринофимы. Продемонстрирована высокая результативность проведенной терапии системным изотретиноином.

rhinophymerosaceasystemic isotretinoinLidoseринофимарозацеасистемный изотретиноинLidoseTan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol 2013;69:27–35. doi: 10.1016/j.jaad.2013.04.043Tüzün Y, Wolf R, Kutlubay Z, Karakuş O, Engin B. Rosacea and rhinophyma. Clin Dermatol 2014;32:35–46. doi: 10.1016/j.clindermatol.2013.05.024Walter S, Krueger S, Ho J, Reddy KK. Unilateral rhinophyma: report of a case and review. PlastAesthet Res 2017;4:49–53. doi: 10.20517/2347-9264.2017.08Marks R, Harcourt-Webster JN. Histopathology of rosacea. Arch Dermatol 1969;100:683–691.Powell FC, Raghallaigh SN. Rosacea and related disorders. In: Bolognia JL, Schaffer JV, Jorizzo JL, editors. Dermatology. 3rd. Philadelphia: Elsevier Saunders; 2012. P. 561–570.Rohrich RJ, Griffin JR, Adams WP. Rhinophyma: review and update. Plast Reconstr Surg. 2002;110(3):860–869; quiz 870. doi: 10.1097/00006534-200209010-00023Jansen T, Plewig G. Clinical and histological variants of rhinophyma, including nonsurgical treatment modalities. Facial Plast Surg. 1998;14(4):241–253. doi: 10.1055/s-2008-1064456el-Azhary RA, Roenigk RK, Wang TD. Spectrum of results after treatment of rhinophyma with the carbon dioxide laser. Mayo Clin Proc. 1991;66(9):899–905. doi: 10.1016/s0025-6196(12)61576-6Keefe M, Wakeel RA, McBride DI. Basal cell carcinoma mimicking rhinophyma. Case report and literature review. Arch Dermatol. 1988;124(7):1077–1079.van Zuuren EJ, Fedorowicz Z, Tan J, van der Linden MMD, Arents BWM, Carter B, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol, 181(2019):65–79. doi: 10.1111/bjd.17590Draelos ZD, Gold MH, Weiss RA, Baumann L, Grekin SK, Robinson DM, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial. J Am Acad Dermatol. 2018;78(6):1156–1163. doi: 10.1016/j.jaad.2018.01.027Del Rosso JQ. Topical ivermectin: data supporting dual modes of action in rosacea. J Clin Aesthet Dermatol. 2017;10(9):39–42.Tan J, Almeida LM, Bewley A, Cribier B, Dlova NC, Gallo R, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSaceaCOnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):431–438. doi: 10.1111/bjd.15122Дрождина М.Б. Фульминантные акне. Современное решение проблемы. Вестник дерматологии и венерологии. 2019;95(4):79–86. [Drozhdina MB. Fulminant acne. Modern solution to the problem. Vestnik Dermatologii i Venerologii. 2019;95(4):79–86 (In Russ.)] doi: 10.25208/0042-4609-2019-95-4-79-86Дрождина М.Б. Болезнь Морбигана. Современный обзор литературы. Описание редкого клинического случая. Медицинский вестник Северного Кавказа. 2020;15(1):129–133. [Drozhdina MB. Morbihan disease. A modern review of the literature. Description of a rare clinical case. Medical news of North Caucasus. 2020;15(1):129–133 (In Russ.)] doi: 10.14300/mnnc.2020.15033Дрождина М.Б., Бобро В.А. Подрывающий фолликулит Гоффмана. Состояние проблемы. Подходы к терапии. Демонстрация клинических случаев. Вестник дерматологии, венерологии и косметологии. 2020;97(2):35–43. [Drozhdina MB, Bobro VA. Goffman's undermining folliculitis. State of the problem. Approach to therapy. Demonstration of clinical cases. Bulletin of Dermatology, Venereology and Cosmetology. 2020;97(2):35–43 (In Russ.)] doi: 10.25208/vdv1139Дрождина М.Б. Применение Акнекутана для лечения фульминантных акне. Консилиум. Дерматовенерология. 2019;2(171):25. [Drozdina MB. The usage of Aknekutan for the treatment of fulminant acne. Consultation. Dermatovenerology. 2019;2(171):25 (In Russ.)]Рябова В.В., Кошкин С.В., Зайцева Г.А., Евсеева А.Л. Характер распределения антигенов HLA II класса у пациентов со средне-тяжелыми и тяжелыми формами акне. Вестник дерматологии и венерологии. 2018;94(2):33–40. [Ryabova VV, Koshkin SV, Zaitseva GA, Evseeva AL. Distribution of HLA class II antigens in patients with moderate-severe and severe forms of acne. Bulletin of Dermatology and Venereology.2018;94(2):33–40 (In Russ.)]Nickle BS, Peterson N, Peterson M. Updated physician's guide to the off-label uses of oral isotretinoin. J Clin Aesthet Dermatol. 2014;7(4):22–34.Gollnick H, Blume-Peytavi U, Szabó EL, Meyer KG, Hauptmann P, Popp G, et al. Systemic isotretinoin in the treatment of rosacea — doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges, 8(2010):505–515. doi: 10.1111/j.1610-0387.2010.07345.xHofer T. Continuous 'microdose' isotretinoin in adult recalcitrant rosacea. Clin Exp Dermatol. 2004;29(2):204–205. doi: 10.1111/j.1365-2230.2004.01472.xUslu M, Şavk E, Karaman G, Şendur N. Rosacea treatment with intermediate-dose isotretinoin: follow-up with erythema and sebum measurements. Acta Derm Venereol. 2012;92(1):73–77. doi: 10.2340/00015555-1204Walsh RK, Endicott AA, Shinkai K. Diagnosis and Treatment of Rosacea Fulminans: A Comprehensive Review. Am J Clin Dermatol. 2018;19(1):79–86. doi: 10.1007/s40257-017-0310-0Korting HC, Schöllmann C. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol, 23(2009):876–882. doi: 10.1111/j.1468-3083.2009.03167.xWee JS, Tan KB. Phymatous rosacea presenting with leonine facies and clinical response to isotretinoin. Australias J Dermatol, 58 (2017). P. 72–73. doi: 10.1111/ajd.12505Haber R, El Gemayel M. Comorbidities in rosacea: A systematic review and update. J Am Acad Dermatol. 2018;78(4):786–792.e8. doi: 10.1016/j.jaad.2017.09.016van Zuuren EJ. Rosacea. N Engl J Med. 2017 Nov 2;377(18):1754–1764. doi: 10.1056/NEJMcp1506630Halioua B, Cribier B, Frey M, Tan J. Feelings of stigmatization in patients with rosacea. J Eur Acad Dermatol Venereol. 2017 Jan;31(1):163–168. doi: 10.1111/jdv.13748Madan V, Ferguson JE, August PJ. Carbon dioxide laser treatment of rhinophyma: a review of 124 patients. Br J Dermatol. 2009;161(4):814–818. doi: 10.1111/j.1365-2133.2009.09317.xPayne WG, Ko F, Anspaugh S, Wheeler CK, Wright TE, Robson MC. Down-regulating causes of fibrosis with tamoxifen: a possible cellular/molecular approach to treat rhinophyma. Ann Plast Surg. 2006;56(3):301–305. doi: 10.1097/01.sap.0000199155.73000.2f